2151 Las Palmas Drive
231 articles with Biocept, Inc.
Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018
Biocept, Inc. announces that it will release financial results for the three and nine months ended September 30, 2018, after the market closes on Tuesday, November 13, 2018.
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing
Biocept, Inc. announces that President and CEO Michael W. Nall will present a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth Conference on October 30, 2018 at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). The conference is being held in Jupiter, Fla.
Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers
Biocept, Inc. announces that President and CEO Michael W. Nall will present a corporate overview at The MicroCap Conference on October 2, 2018, at 11:30 a.m. Eastern time (8:30 a.m. Pacific time).
Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids
Biocept, Inc. today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock
Mr. Hendrick brings to Biocept over 25 years of sales and commercial leadership experience in the healthcare industry
Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
Allegheny Health Network's Cancer Institute spearheading the evaluation
Company to host conference call at 4:30 p.m. Eastern time today
The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $11.6 million in gross proceeds.
Further expands global patent estate for capturing and detecting biological targets of interest including rare cells such as circulating tumor cells (CTCs)
European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)
Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy
Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring
To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing
Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region
Expands international distribution of Target Selector™ platform to 17 countries
Biocept, Inc. provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering.
Published Case Report Demonstrates the Clinical Utility of Biocept's CTC Platform in the Management of Patients with Metastatic Breast Cancer
Peer-reviewed article in journal Clinics in Oncology highlights ability of Biocept's Target Selector™ to detect a key biomarker to qualify breast cancer patients for targeted therapy when tissue biopsy is inconclusive
VWR, Part of Avantor, and Biocept Announce the Launch of CEE-Sure Blood Collection Tubes for cfDNA and CTCs
Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature
Biocept, Inc. announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at LD Micro Invitational Conference on Tuesday, June 5, 2018, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time).